• 

  New Antibiotic Packs a Punch Against Bacterial Resistance

  Scientists at Scripps Research have given new superpowers to a lifesaving antibiotic called vancomycin, an advance that could eliminate the threat of antibiotic-resistant infections for years to come.

• HitGen Announces Drug Discovery Collaboration with the Scripps Research Institute and the California Institute for Biomedical Research (Calibr)

  Leaders in basic and translational research at TSRI and Calibr will provide target materials and relevant know‐how to prosecute drug targets of interest.

• 

  Chemists Devise Simple Method for Making Sought-After Boronic Acid-Based Drugs and Other Products

  Initial demonstrations yield compounds with promise for treating COPD, cystic fibrosis and other lung disorders.

• Scientists Discover New Class of Anti-Diabetes Compounds that Reduce Liver Glucose Production

  Scientists may have found a new tool for studying—and maybe even treating—Type 2 diabetes, the form of diabetes considered responsible for close to 95 percent of cases in the United States.

• Potential Drug Candidates Halt Prostate and Breast Cancer Growth

  Next, the researchers plan to further develop their molecule-screening strategy into a platform to test molecules against any form of RNA defect-related disease.

• TSRI Chemists Unveil Versatile New Method for Making Chiral Drug Molecules

  "This method essentially mimics the ability of the enzymes in our cells to turn simple organic molecules into chiral molecules."

• Scripps Florida Team Awarded $1.8 Million Grant to Develop Drugs for Heart Disease and Rheumatoid Arthritis

  The co-principal investigators of the three-year project are TSRI Professor William R. Roush and Associate Professor Derek Duckett.

• 

  New TSRI Method Could Turbocharge Drug Discovery, Protein Research

  A team led by scientists at Scripps Research has developed a versatile new method that should enhance the discovery of new drugs and the study of proteins.

• 

  The Scripps Research Institute Signs Collaboration Agreement with Pfizer to Advance DNA-Encoded Library Technology

  The Scripps Research Institute (TSRI), a leading non-profit biomedical research institute, today announced a research collaboration and license agreement with Pfizer Inc. (NYSE: PFE) to pioneer new DNA-encoded library (DEL) technology.

• Calibr News: Intarcia and Calibr Announce New Collaboration and In-Licensing Deal

  Calibr, a corporate affiliate of The Scripps Research Institute, has announced a strategic research collaboration with Intarcia Therapeutics, Inc.